← Back to Search

Other

PF-07081532 for Diabetes

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post dose on study day 1 and study day 42

Summary

This trial tests a new drug called PF-07081532 to see if it is safe and how it behaves in the body. It targets people with type 2 diabetes who are not well-controlled on their current medication and some people with obesity. Participants will take the drug daily for several weeks while researchers monitor its effects.

Eligible Conditions
  • Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post dose on study day 1 and study day 42
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post dose on study day 1 and study day 42 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Number of Participants With Pre-specified Categorical Post-Baseline Electrocardiogram (ECG) Data
Number of Participants With Pre-specified Categorical Post-Baseline Vital Signs Data
+2 more
Secondary study objectives
Area Under the Concentration-Time Profile From 0 to 24 Hours (AUC24) of PF-07081532 on Day 1 and Day 42
Maximum Observed Plasma Concentration (Cmax) of PF-07081532 on Day 1 and Day 42
Terminal Half-life (t1/2) of PF-07081532 on Day 42
+1 more

Side effects data

From 2021 Phase 1 trial • 66 Patients • NCT04305587
14%
Dyspepsia
14%
Diarrhoea
14%
Decreased appetite
14%
Vaccination complication
14%
Dermatitis contact
100%
80%
60%
40%
20%
0%
Study treatment Arm
PF-07081532 10 mg Part A
Placebo Part A
PF-07081532 30 mg Part A
PF-07081532 60 mg Part A
PF-07081532 120 mg Part A
Placebo Part B
PF-07081532 180 mg Part B
Placebo Part C
PF-07081532 180 mg Part C

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-07081532Experimental Treatment1 Intervention
multiple dosing, once-daily for 42 days
Group II: PlaceboPlacebo Group1 Intervention
multiple dosing, once-daily for 42 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07081532
2022
Completed Phase 1
~170

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,661 Previous Clinical Trials
17,844,955 Total Patients Enrolled
12 Trials studying Diabetes
107,251 Patients Enrolled for Diabetes
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,546 Previous Clinical Trials
14,886,111 Total Patients Enrolled
1 Trials studying Diabetes
151 Patients Enrolled for Diabetes
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top